TY - STD TI - Pfizer. BOSULIF (bosutinib). Prescribing information (updated December 2017). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203341s009lbl.pdf. Accessed 7 June 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203341s009lbl.pdf ID - ref1 ER - TY - STD TI - European Medicines Agency. BOSULIF (bosutinib). Summary of product characteristics (updated May 2018). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002373/WC500141721.pdf. Accessed 7 June 2018. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002373/WC500141721.pdf ID - ref2 ER - TY - JOUR AU - Cortes, J. E. AU - Kantarjian, H. M. AU - Brümmendorf, T. H. AU - Kim, D. W. AU - Turkina, A. G. AU - Shen, Z. X. PY - 2011 DA - 2011// TI - Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-05-355594 DO - 10.1182/blood-2011-05-355594 ID - Cortes2011 ER - TY - JOUR AU - Khoury, H. J. AU - Cortes, J. E. AU - Kantarjian, H. M. AU - Gambacorti-Passerini, C. AU - Baccarani, M. AU - Kim, D. W. PY - 2012 DA - 2012// TI - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-11-390120 DO - 10.1182/blood-2011-11-390120 ID - Khoury2012 ER - TY - JOUR AU - Cortes, J. E. AU - Kim, D. W. AU - Kantarjian, H. M. AU - Brümmendorf, T. H. AU - Dyagil, I. AU - Griskevicius, L. PY - 2012 DA - 2012// TI - Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.7522 DO - 10.1200/JCO.2011.38.7522 ID - Cortes2012 ER - TY - JOUR AU - Cortes, J. E. AU - Gambacorti-Passerini, C. AU - Deininger, M. W. AU - Mauro, M. J. AU - Chuah, C. AU - Kim, D. W. PY - 2018 DA - 2018// TI - Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.74.7162 DO - 10.1200/JCO.2017.74.7162 ID - Cortes2018 ER - TY - JOUR AU - Gambacorti-Passerini, C. AU - Cortes, J. E. AU - Lipton, J. H. AU - Kantarjian, H. M. AU - Kim, D. W. AU - Schafhausen, P. PY - 2018 DA - 2018// TI - Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study JO - Haematologica VL - 103 UR - https://doi.org/10.3324/haematol.2017.171249 DO - 10.3324/haematol.2017.171249 ID - Gambacorti-Passerini2018 ER - TY - JOUR AU - Cortes, J. E. AU - Khoury, H. J. AU - Kantarjian, H. M. AU - Lipton, J. H. AU - Kim, D. W. AU - Schafhausen, P. PY - 2016 DA - 2016// TI - Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib JO - Am J Hematol VL - 91 UR - https://doi.org/10.1002/ajh.24536 DO - 10.1002/ajh.24536 ID - Cortes2016 ER - TY - JOUR AU - Brümmendorf, T. H. AU - Cortes, J. E. AU - Souza, C. A. AU - Guilhot, F. AU - Duvillie, L. AU - Pavlov, D. PY - 2015 DA - 2015// TI - Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial JO - Br J Haematol VL - 168 UR - https://doi.org/10.1111/bjh.13108 DO - 10.1111/bjh.13108 ID - Brümmendorf2015 ER - TY - JOUR AU - Gambacorti-Passerini, C. AU - Brümmendorf, T. H. AU - Kim, D. W. AU - Turkina, A. G. AU - Masszi, T. AU - Assouline, S. PY - 2014 DA - 2014// TI - Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up JO - Am J Hematol VL - 89 UR - https://doi.org/10.1002/ajh.23728 DO - 10.1002/ajh.23728 ID - Gambacorti-Passerini2014 ER - TY - JOUR AU - Prasad, V. AU - Massey, P. R. AU - Fojo, T. PY - 2014 DA - 2014// TI - Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.0204 DO - 10.1200/JCO.2013.53.0204 ID - Prasad2014 ER - TY - JOUR AU - Medeiros, B. C. AU - Possick, J. AU - Fradley, M. PY - 2018 DA - 2018// TI - Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing JO - Blood Rev VL - 32 UR - https://doi.org/10.1016/j.blre.2018.01.004 DO - 10.1016/j.blre.2018.01.004 ID - Medeiros2018 ER - TY - JOUR AU - Rosti, G. AU - Castagnetti, F. AU - Gugliotta, G. AU - Baccarani, M. PY - 2017 DA - 2017// TI - Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? JO - Nat Rev Clin Oncol VL - 14 UR - https://doi.org/10.1038/nrclinonc.2016.139 DO - 10.1038/nrclinonc.2016.139 ID - Rosti2017 ER - TY - STD TI - Novartis. GLEEVEC (imatinib mesylate). Prescribing information (updated July 2018). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf. Accessed 17 Sept 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf ID - ref14 ER - TY - STD TI - Novartis. TASIGNA (nilotinib). Prescribing information (updated July 2018). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s029lbl.pdf. Accessed 17 Sept 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s029lbl.pdf ID - ref15 ER - TY - STD TI - Bristol-Myers Squibb. SPRYCEL (dasatinib). Prescribing information (updated November 2017). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021986s020lbl.pdf. Accessed 16 Aug 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021986s020lbl.pdf ID - ref16 ER - TY - STD TI - ARIAD Pharmaceuticals. ICLUSIG (ponatinib). Prescribing information (updated December 2017). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203469s027s028lbl.pdf. Accessed 17 Sept 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203469s027s028lbl.pdf ID - ref17 ER - TY - STD TI - Incyte Biosciences UK Ltd. ICLUSIG (ponatinib). Summary of product characteristics (updated August 2018). Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002695/WC500145646.pdf. Accessed 20 Sept 2018. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002695/WC500145646.pdf ID - ref18 ER - TY - JOUR AU - Hochhaus, A. AU - Saussele, S. AU - Rosti, G. AU - Mahon, F. X. AU - Janssen, J. AU - Hjorth-Hansen, H. PY - 2017 DA - 2017// TI - Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx219 DO - 10.1093/annonc/mdx219 ID - Hochhaus2017 ER - TY - JOUR AU - Pophali, P. A. AU - Patnaik, M. M. PY - 2016 DA - 2016// TI - The role of new tyrosine kinase inhibitors in chronic myeloid leukemia JO - Cancer J VL - 22 UR - https://doi.org/10.1097/PPO.0000000000000165 DO - 10.1097/PPO.0000000000000165 ID - Pophali2016 ER - TY - JOUR AU - Blay, J. Y. AU - Mehren, M. PY - 2011 DA - 2011// TI - Nilotinib: a novel, selective tyrosine kinase inhibitor JO - Semin Oncol VL - 38 UR - https://doi.org/10.1053/j.seminoncol.2011.01.016 DO - 10.1053/j.seminoncol.2011.01.016 ID - Blay2011 ER - TY - JOUR AU - Lin, Y. L. AU - Roux, B. PY - 2013 DA - 2013// TI - Computational analysis of the binding specificity of Gleevec to Abl, c-kit, Lck, and c-Src tyrosine kinases JO - J Am Chem Soc VL - 135 UR - https://doi.org/10.1021/ja405939x DO - 10.1021/ja405939x ID - Lin2013 ER - TY - JOUR AU - Kota, V. AU - Brümmendorf, T. AU - Gambacorti-Passerini, C. AU - Cortes, J. AU - Lipton, J. AU - Kantarjian, H. PY - 2016 DA - 2016// TI - Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive chronic myeloid leukemia JO - Blood VL - 128 ID - Kota2016 ER - TY - JOUR AU - Brümmendorf, T. H. AU - Gambacorti-Passerini, C. AU - Hochhaus, A. AU - Lipton, J. H. AU - Kota, V. AU - Deininger, M. W. PY - 2018 DA - 2018// TI - Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial JO - Blood VL - 132 ID - Brümmendorf2018 ER - TY - JOUR AU - Garrett, M. AU - Knight, B. AU - Cortes, J. AU - Deininger, M. PY - 2017 DA - 2017// TI - Optimizing dose of bosutinib to minimize adverse events while maintaining efficacy in patients with newly diagnosed chronic myelogenous leukemia JO - Blood VL - 130 ID - Garrett2017 ER - TY - JOUR AU - Gambacorti-Passerini, C. AU - Kantarjian, H. M. AU - Kim, D. W. AU - Khoury, H. J. AU - Turkina, A. G. AU - Brümmendorf, T. H. PY - 2015 DA - 2015// TI - Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors JO - Am J Hematol VL - 90 UR - https://doi.org/10.1002/ajh.24034 DO - 10.1002/ajh.24034 ID - Gambacorti-Passerini2015 ER - TY - STD TI - National Comprehensive Cancer Network (NCCN Guidelines®). Chronic myeloid leukemia. Available at https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf (password restricted). Accessed 15 Aug 2018. UR - https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf ID - ref27 ER - TY - JOUR AU - Kantarjian, H. M. AU - Cortes, J. E. AU - Kim, D. W. AU - Khoury, H. J. AU - Brümmendorf, T. H. AU - Porkka, K. PY - 2014 DA - 2014// TI - Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-07-513937 DO - 10.1182/blood-2013-07-513937 ID - Kantarjian2014 ER - TY - JOUR AU - Khoury, H. J. AU - Gambacorti-Passerini, C. AU - Brümmendorf, T. H. PY - 2018 DA - 2018// TI - Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy019 DO - 10.1093/annonc/mdy019 ID - Khoury2018 ER - TY - JOUR AU - Cortes, J. E. AU - Gambacorti-Passerini, C. AU - Kim, D. W. AU - Kantarjian, H. M. AU - Lipton, J. H. AU - Lahoti, A. PY - 2017 DA - 2017// TI - Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias JO - Clin Lymphoma Myeloma Leuk VL - 17 UR - https://doi.org/10.1016/j.clml.2017.06.001 DO - 10.1016/j.clml.2017.06.001 ID - Cortes2017 ER - TY - JOUR AU - Vidal-Petiot, E. AU - Rea, D. AU - Serrano, F. AU - Stehle, T. AU - Gardin, C. AU - Rousselot, P. PY - 2016 DA - 2016// TI - Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia JO - Clin Lymphoma Myeloma Leuk VL - 16 UR - https://doi.org/10.1016/j.clml.2015.12.001 DO - 10.1016/j.clml.2015.12.001 ID - Vidal-Petiot2016 ER - TY - STD TI - Cortes JE, Khoury HJ, Kantarjian H, Brümmendorf TH, Mauro MJ, Matczak E, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91:606–16. ID - ref32 ER - TY - STD TI - Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81. ID - ref33 ER - TY - JOUR AU - Goff, D. C. AU - Lloyd-Jones, D. M. AU - Bennett, G. AU - Coady, S. AU - D'Agostino, R. B. AU - Gibbons, R. PY - 2014 DA - 2014// TI - 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines JO - Circulation VL - 129 UR - https://doi.org/10.1161/01.cir.0000437741.48606.98 DO - 10.1161/01.cir.0000437741.48606.98 ID - Goff2014 ER - TY - JOUR AU - Yancy, C. W. AU - Jessup, M. AU - Bozkurt, B. AU - Butler, J. AU - Casey, D. E. AU - Drazner, M. H. PY - 2013 DA - 2013// TI - 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines JO - J Am Coll Cardiol VL - 62 UR - https://doi.org/10.1016/j.jacc.2013.05.019 DO - 10.1016/j.jacc.2013.05.019 ID - Yancy2013 ER - TY - JOUR AU - Yancy, C. W. AU - Jessup, M. AU - Bozkurt, B. AU - Butler, J. AU - Casey, D. E. AU - Drazner, M. H. PY - 2013 DA - 2013// TI - 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines JO - Circulation VL - 128 UR - https://doi.org/10.1161/CIR.0b013e31829e8807 DO - 10.1161/CIR.0b013e31829e8807 ID - Yancy2013 ER -